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Sodium intake and renal responses to captopril in normal man and in
essential hypertension. We assessed the renal vascular and functional
response to converting enzyme inhibition with captopril in 53 normal
subjects and 78 patients with essential hypertension, all studied when in
balance on either a 10- or 200-mEq sodium and l00-mEq potassium
intake. Mean renal blood flow, assessed with radioxenon, showed a
dose and time-related increase in normal subjects on a restricted sodium
intake. Mean renal blood flow, assessed with radioxenon, showed a
dose- and time-related increase in normal subjects on a restricted
sodium intake; 10- and 25-mg oral captopril doses induced an identical
peak response (92 8 and 83 12 ml/l00 g/min, respectively), which
reached a plateau within 30 mm. A smaller but significant blood flow
increase occurred in the normal subjects on a high sodium intake (45
16 and 46 18 mlIlOO g/min, respectively). Patients with essential
hypertension showed a potentiated increase in renal blood flow on both
the low sodium (132 6 ml/lOO glmin) and high sodium intake (82 14
ml/100 g/min). Creatinine clearance fell in normal subjects, but in
patients with essential hypertension, in whom creatinine clearance
either did not change, or in 8 patients whose creatinine clearance was
below normal, it rose by 20 8 ml/min/1.73 m2 (P < 0.01). A rise in
sodium excretion and a fall in potassium excretion occurred in all
groups.' Differences in response between the normal subjects and
patients with essential hypertension could not be accounted for on the
basis of differences in the fall in blood pressure or plasma angiotensin II
concentration. We conclude that captopril induces renal vasodilatation
in normal man and a potentiated response in patients with essential
hypertension, which is consistent with a functional abnormality involv-
ing the kidney in this state. Moreover, the potentiated response in
essential hypertension, and the accompanying natriuresis, has function-
al implications that may well contribute to captopril's therapeutic use.
Ingestion de sodium et réponse rénale au captopril chez l'homme
normal et au cours de l'hypertension essentielle. Nous avons évalué Ia
réponse vasculaire et fonctionnelle du rein a l'inhibition de l'enzyme de
conversion par le captopril chez 53 sujets normaux et 78 malades
atteints d'hypertension essentielle, tous étudiés alors qu'ils étaient
soumis a un apport de 10 ou 200 mEq de sodium et 100 mEq de
potassium. Le debit sanguin renal moyen, évalué par le radioxénon, a
montré une augmentation fonction de la dose et du temps chez les sujets
normaux soumis a une restriction de sodium. Des doses de 10 et 25 mg
de captopril ont déterminé un pic de réponse identique (92 8 et 83
12 mlIlOO g/min, respectivement), puis un plateau atteint en 30 minutes.
Une augmentation du debit sanguin plus faible mais significative est
intervenue chez les sujets normaux soumis a l'apport élevé de sodium
(45 16 et 46 18 ml/100 glmin). Les malades atteints d'hypertension
essentielle avaient une augmentation du debit sanguin renal aussi bien
avec Ic régime pauvre (132 6 ml/100 glmin) qu'avec Ic régime riche (82
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14 ml/lOO g/min). La clearance de Ia crëatinine a diminué chez les
sujets normaux mais pas chez les malades atteints d'hypertension
essentielle, chez lesquels elle n'a pas change ou bien a augmenté, cela
chez 8 malades dont les clearances de Ia créatinine étaient inférieures
aux valeurs normales, de 20 8 ml/min/l,73 m2 (P < 0,01). Une
augmentation de l'excrétion du sodium et une diminution de l'excrétion
du potassium ont été observées dans tous les groupes. Les differences
de réponse entre les sujets normaux et les malades atteints d'hyperten-
sion essentielle ne peuvent pas être expliquees par des differences dans
Ia chute de Ia pression artérielle ou de Ia concentration plasmatique
d'angiotensine II. Nous concluons que le captopril determine une
vasodjlatation rénale chez l'homme normal et une réponse potentialisée
chez les malades atteints d'hypertension essentielle, ce qui est en
accord avec une anomalie fonctionnelle impliquant le rein dans cet Ctat.
Dc plus, Ia reponse potentialisée dans l'hypertension essentielle, et Ia
natriurèse qui l'accompagne, a des implications fonctionnelles qui
pourraient contribuer a l'utilité therapeutique du captopril.
Multiple observations have suggested that a functional abnor-
mality accounts for, at least in part, the reduction in renal blood
flow [1, 2] and glomerular filtration [3] in the patient with
essential hypertension. The evidence has arisen partly from an
enhanced renal vascular response to a wide variety of vasodila-
tor agents, including the peptide converting enzyme inhibitor
SQ 20881 or teprotide [4]. The development of captopril, the
converting enzyme inhibitor that is effective when taken by
mouth and that has been effective in the management of even
drug-resistant hypertension [5—8], led to this study, which
focuses on the renal response to this agent.
Methods
Subjects. Renal blood flow (RBF) studies with radioxenon
were carried out at the time of angiography in 32 normal
subjects who were potential kidney donors and in 16 patients
with essential hypertension. The age range was 18 to 63 years in
the normal subjects and 20 to 62 years in the patients with
essential hypertension. Metabolic balance studies and the as-
sessment of glomerular filtration rate (GFR) were carried out in
an additional 21 normal subjects and 62 patients with essential
hypertension. All patients were admitted to a metabolic ward
where they received a careful evaluation with special emphasis
on cardiovascular, renal, and adrenal status [1—4]. They were
also placed on a diet that provided a daily intake of either 10 or
200 mEq of sodium and 100 mEq of potassium for at least 5 days
prior to study. Balance was assessed by measurement of
sodium excretion in 24-hour urine collections, by a detailed
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assessment of daily dietetic intake, and by serial weight mea-
surements.
Essential hypertension was diagnosed by exclusion after a
thorough evaluation, which has been described in detail [1—4].
Protocols and techniques. Percutaneous selective renal arte-
rial catheterization, the determination of RBF with radioactive
xenon ('33Xe), external monitoring with a probe-mounted scin-
tillation detector, and cardiovascular monitoring during the
administration of vasoactive agents in the cardiovascular labo-
ratory have been described in detail [11. The arterial catheter
was used for the continuous monitoring of blood pressure and
heart rate, for injecting '33Xe, and for drawing arterial blood
samples for measurement of electrolytes and hormones. Blood
pressure was measured with a transducer (Statham P23dB) and
recorded continuously along with the instantaneous pulse rate
and the electrocardiogram. Continuous monitoring insured pa-
tient safety and cardiovascular stability, and it made it possible
to make an accurate measurement of the small blood pressure
changes that occurred with captopril.
Blood flow studies were initiated at least 30 mm after blood
pressure stability was achieved following aortography. A con-
trol blood flow determination was obtained, and a control
arterial blood sample was drawn for the measurement of plasma
renin activity (PRA), angiotensin II (All), bradykinin, aldoster-
one, cortisol, sodium, and potassium concentrations. The sub-
ject or patient then received a single dose of captopril (5, 10, or
25 mg) by mouth. Blood flow determinations and arterial blood
samples for hormone analysis were then repeated at 10-mm
intervals for at least 40 mm.
In the second group of 21 normal subjects and 62 patients
with essential hypertension, the influence of the agent on
creatinine clearance, used as an index of GFR, and on sodium
and potassium excretion was assessed on a metabolic ward.
The clearance techniques that we use have been described in
detail [31. The subjects were studied in the recumbent position
in their hospital beds after a 10-hour fast. At 7 A.M., a diuresis
was initiated with 10 to 20 ml of water per kg of body weight
taken by mouth. Needles were placed in forearm veins to allow
serum blood samples to be drawn without repeated venipunc-
ture. A diuresis of 10 mI/mm or more ensued; urine samples
were obtained after spontaneous voiding at 30- to 40-mm
intervals without urethral catheterization. After each collec-
tion, the volume of urine sample was measured, and the patient
then drank an equal volume of water to maintain the diuresis.
Plasma renin activity, All, bradykinin, serum creatinine, sodi-
um, and potassium concentrations were measured in blood
samples collected at 30-mm intervals during the protocol.
Studies were performed on two separate days: first, one or
more days prior to captopril administration; second, several
days later, at the same time of day. On the second study day,
the patient received a single dose of captopril, over a dose range
of 10 to 100 mg by mouth, and urine and blood samples were
collected at intervals for the following 6 hours. Four to eight
collections were made for each clearance. The clearance and
excretion values are reported as the geometric mean of these
various samples before and during converting enzyme inhibi-
tion.
Analytic techniques. All blood samples were collected in
plastic syringes, placed on ice, spun immediately at 4° C, and
the plasma was frozen until time for assay. The anticoagulant
was ethylenediaminetetracetate (EDTA) for bradykinin, PRA,
and All samples. Diisofluorophosphate was also added to the
samples for All assay.
Samples for bradykinin measurement were collected in pre-
chilled polypropylene tubes containing 0.36 mg of polybrene (to
inhibit Hageman factor and thereby bradykinin generation) and
0.9 mg of EDTA (to inhibit kininases and thereby bradykinin
destruction). To precipitate proteins, 0.25 ml of 20% trichlora-
cetic acid was added to 5 ml of plasma. The supernatant was
chromatographed on an Amberlite CG-50 column, washed with
0.1 ml of acetic acid, and taken for radioimmunoassay with
polyethylene glycol to separate bound and free [4].
Angiotensin II was measured by a double-antibody radio-
immunoassay method [9]. PRA was measured by radio-
immunoassay of angiotensin I (Al) generated during a 30-mm
incubation with endogenous substrate at 37° C [9]. The bradyki-
nm assay was performed by radioimmunoassay [4]. Captopril
did not crossreact with any antibody used in radioimmuno-
assay.
Creatinine concentration in urine and serum was determined
by the autoanalyzer method. Sodium and potassium concentra-
tions in urine and serum were measured by flame photometry,
with lithium as an internal standard.
Mean RBF was measured from the initial slope of '33Xe
disappearance from the kidney, determined graphically, with a
hematocnt-corrected partition coefficient. Because RBF re-
sponses to captopril had plateaued by 30 mm, the average of the
30- and 40-mm determinations was used to calculate the re-
sponse. Because by 30 mm the 10- and 25-mg captopril doses
had induced an identical maximal response in all subjects, data
obtained with the two doses were pooled for comparing the
normal subjects and patients with essential hypertension.
Group means were calculated with the SEM as the index of
dispersion. The evaluation of statistical probability was carried
out, where appropriate, using Dunnett's tables for multiple
comparisons or Student's paired data t test. Otherwise, the
Wilcoxon rank sum (WRST) or Fisher exact test (FET) for
nonparametric data was used. The null hypothesis was rejected
when P < 0.05.
The protocol was approved by the Human Experimentation
Committees of the Peter Bent Brigham Hospital and Harvard
Medical School. Written permission for the procedure was
obtained from each patient after a detailed description of the
protocols.
Results
Renal blood flow studies. The baseline values for blood
pressure, RBF, plasma renin activity, and plasma All concen-
tration for the studies focussed on RBF are summarized in
Table 1. As anticipated, arterial blood pressure was significant-
ly higher (P < 0.01), but no other significant differences were
found between the normal subjects and the patients with
essential hypertension. When RBF was normalized for age and
sodium intake, as described earlier [1], RBF in the patients with
essential hypertension was 87.8 5.1% of predicted, signifi-
cantly less than that in the normal subjects (99.3 9.5%; P <
0.025).
Captopril induced a dose- and time-related increase in RBF in
both the normal subjects and in the patients with essential
hypertension (Figs. 1 and 2). The 5-mg dose increased blood
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Essential
Normal hypertension
With low salt balance
BP, mm Hg 85 4 105 5
RBF, mi/100 glmin 303 14 276 23
PRA, ngAI/mi/hr 3.3 0.4 3.1 0.6
All, pg/mi 33 4.7 33 6.7
Number studied 15 9
With high salt balance
BP, mm Hg 89 4 107 18
RBF, mi/100 g/min 333 23 309 16
PRA, ng Al/mi/hr 1.9 0.2 2.1 0.4
All, pg/mi 23 4.0 25 4.1
Number studied 17 7
I Na restricted I
I I I 1 t i I
0 10 20 30 37 0 10 20 30 37
Time, rn/n
Fig. 1. Influence of graded doses of captopril on renal perfusion in
normal man. Note that 10 and 25 mg induced an identical peak change,
which had occurred within 30 mm on both diets.
flow significantly (from 355 65 to 391 21 ml per 100 g/min; P
<0.05) in normal subjects on a low salt diet (Fig. 1). Increasing
the dose to 10 and 25 mg induced a progressively more rapid
response, but both doses induced the same maximal flow
increase, 92 8 and 83 12 ml per 100 g/min, respectively,
which stabilized within 30 mm (Fig. 1).
In the subjects studied on a high sodium intake, to suppress
plasma renin activity and reduce plasma All concentration, an
increase in RBF occurred with 10- and 25-mg doses, but not the
5-mg dose (Fig. 1). Again, the 10- and 25-mg doses induced the
same maximal response in the normal subjects, an increase of
45 16 and 46 18 ml per 100 g/min, respectively. The peak
response in the subjects on a high salt diet was significantly
lower than that in the subjects on a low salt diet (P <0.01).
No blood pressure response occurred to a 5-mg captopril
dose on either diet in the normal subjects. The 10- and 25-mg
doses induced a small but significant blood pressure fall, which
was generally about 5 mm Hg, and which varied neither with
dose nor diet.
The patients with essential hypertension showed a potentiat-
ed renal vascular response to captopril whether the study was
performed on a reduced (P <0.001) or liberal (P <0.01) sodium
Fig. 2. Captopril's effect of inducing a larger increase in RBF in
patients with essential hypertension than it does in normal subjects
whether on a sodium restricted intake or on a liberal sodium intake.
Mean arterial blood pressure showed a significantly larger fall in the
patients with essential hypertension only when sodium intake was
restricted.
intake (Fig. 2). The mean peak flow increase averaged 132 6
ml per 100 g/min in the hypertensive patients on a low sodium
intake, and 82 14 mlIlOO glmin in those on a liberal sodium
intake.
The blood pressure fall in the patients with essential hyper-
tension exceeded that in the normal subjects when the studies
were performed on a sodium-restricted intake, but not when a
liberal sodium intake was allowed (Fig. 2).
No systematic change could be perceived in the renal arterio-
gram following captopril, even in patients in whom a particular-
ly striking increase in RBF occurred.
Captopril induced a similar pattern of change in plasma renin
activity and plasma All concentration in the normal subjects
and the patients with essential hypertension (Fig. 3). In the
normal subjects, plasma All concentration had fallen from 38
8 to 25 3 pg/mi (P < 0.05) within 10 mm of ingestion, and
plateaued by 20 mm (20 2 pg/mI; P < 0.01). A similar pattern
was evident in the patients with essential hypertension, where
the 10-mg dose reduced plasma All concentration from 33 7
to 23 4 at 10 mm (P < .01), to a nadir of 21 4 pg/mI (P <
0.01) at 40 mm. Plasma renin activity rose over the same time
course to a similar degree in both groups (P < 0.01). Plasma
bradykinin concentration did not change significantly in the
normal subjects, and rose only transiently in the patients with
essential hypertension (2.2 0.6 vs. 3.2 0.9 ng/ml; P < 0.05)
at 10 mm.
In studies performed when balance was achieved on a high
sodium intake, despite suppression of the renin-angiotensin
system, a significant fall occurred in plasma All concentration
Table 1. Baseline values for blood flow studies
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T
Na restricted 1
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Abbreviations are defined as follows: BP, blood pressure; RBF,
renal blood flow; PRA, plasma renin activity; All, angiotensin II; Al,
angiotensin I. Except for the number studied, all values are the means
SEM.
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Fig. 3. Influence of captopril on plasma renin activity (PRA), plasma
angiotensin ii concentration (PA,,), and plasma bradykinin concentra-
tion (PBK) in normal subjects and in patients with essential hyperten-
sion. The closed circles represent studies performed on a sodium
restricted intake; and the open circles, those on a liberal sodium intake.
Captopril resulted in a significant increase in PRA and a significant
reduction in plasma All concentration on both diets. No difference was
found between the normal subjects and patients with hypertension.
in normal subjects (23 7 vs. 16 4 pg/mi; P < 0.01) and in the
patients with essential hypertension (25 4 vs. 19 6 pg/mI; P
< 0.01). Plasma renin activity showed a small but significant
increase (P < 0.01) in both groups. No changes in plasma
bradykinin concentration occurred. Again, there were no statis-
tically significant differences in the responses to the 10- and 25-
mg doses.
A correlation was found between baseline plasma renin
activity and the change in RBF in the normal subjects (r = 0.66;
F = 20.6;P < 0.001). A correlation was also found between the
control plasma renin activity and the fall in mean arterial blood
pressure (r = —0.50; F = 8.81; P < 0.01). Similar correlations
could not be found between the hormonal indices and changes
in blood pressure and RBF in the patients with essential
hypertension.
Prior to captopril administration, in the clearance studies the
normal subjects and the hypertensive patients differed in only
one respect: mean arterial pressure was lower in the normal
subjects (83 1.8 vs. 107 1.8 mm Hg; P < 0.001; Table 2).
They did not differ in plasma renin activity, All, or bradykinin
concentrations, in the rate of sodium excretion or creatinine
clearance.
Arterial blood pressure again showed a larger fall in the
patients with essential hypertension than it did in the normal
subjects, all studied on a restricted sodium intake (—12.3 1.1
vs. —4.9 0.8 mm Hg; P < 0.001). Despite the larger fall in
arterial pressure in the patients with essential hypertension,
creatinine clearance remained essentially unchanged (4 3
mllmin per 1.73 m2), which differed significantly from the
normal subjects (—11 7 mI/mm; P < 0.02 WRST). In 8
patients in whom the control clearance was below 90 ml/min per
1.73 m2, our lower limit of normal, creatinine clearance rose by
26% (Table 2). These patients did not differ from the patients
with essential hypertension in whom the control creatinine
clearance was in the normal range in any of the indices assessed
(Table 2).
A significant increase in sodium excretion (P <0.01) and a
significant fall in potassium excretion (P < 0.01) occurred in
both the normal subjects and in the patients with essential
hypertension (Table 1). There were no differences between
groups.
Discussion
As anticipated from earlier experience with converting en-
zyme inhibition induced by teprotide in normal subjects ingest-
ing a restricted sodium intake [4, 10], captopril induced a fall in
plasma All concentration, and with it a fall in blood pressure,
an increase in renal perfusion, and a reactive increase in plasma
renin activity. No change occurred in plasma bradykinin con-
centration. The only surprise was the rapidity of the response to
captopril taken by mouth; the onset of action was clearly less
than 10 mm, and the dose required to induce a response was
very small. The threshold dose was clearly less than 5 mg, and
the maximal endocrine and renal response was achieved with a
10-mg dose: increasing the dose to 25 mg only increased the
rapidity of the onset of the response, and presumably prolonged
the duration [6], although this was not assessed directly in this
study. Our data are consistent with the suggestion that larger
doses prolong the duration but do not enhance the magnitude of
the response [6].
The findings in the subjects ingesting a substantial sodium
intake were not anticipated. Plasma All concentration showed
a small, but statistically significant and consistent fall. Blood
pressure fell and RBF increased, although both responses were
less than those in the subjects on a reduced sodium intake.
Teprotide, conversely, induced none of these responses in
subjects ingesting a substantial sodium intake in our earlier
studies [4, 10]. Whether this difference reflects a fundamental
difference in the agent or just reflects a dosage difference is not
clear. The limited amounts of teprotide available led to a
sharply reduced dose range over which we worked in earlier
studies, the largest dose used in a subject on a high salt diet
being 100 p.g/kg. The threshold captopril dose to induce a
response in subjects on a high sodium intake, 10 mg, on a molal
basis is about ten times larger than the largest teprotide dose we
used.
Several candidates exist as mediators of the renal vascular
response. Multiple lines of evidence suggest that angiotensin
plays a major role in the renal response when the renin-
angiotensin system is activated [111. The renal circulation is
extraordinarily sensitive to All in normal man [12], and the
sharp reduction in All concentration that we documented
paralleled in time the renal vascular response, and thus could
have been a major contributor. A fall in plasma All concentra-
tion also occurred in the subjects ingesting a high sodium
intake, albeit smaller, and the renal response to captopril was
reduced. Zimmerman has found that infusion of saralasin, the
angiotensin antagonist, totally abolishes the RBF increase
induced by captopril in the dog, even under conditions of
hemorrhagic hypotension (personal communication). We have
made similar observations in the anesthetized rabbit (unpub-
lished data). The residual influence of captopril when the renin-
angiotensin system was suppressed could have reflected, there-
fore, a reduced but still present action of angiotensin—or an
action of captopril on other systems, especially those involving
bradykinin degradation or prostaglandin formation.
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Table 2. Influence of captopril on renal function
Normal
Essential hypertension
All patients
Creatinine clearance
<90
90(N = 21) (N = 62) (N = 8) (N = 54)
BP, mm Hg 83.2 1.8 107 1.8 109 4.5 106 2.0
BP
—5.0 0,8
—12.3 1.1
—10.1 3.4 —12.6 1.2
Ce,-, ml/min/1.73 m2 132 6.1 122 3.6 77 2.9 128 3.2
LCcr 10.7 6.8 3.9 3.2 20.3 8.1 1.4 3.4
PRA, ngAI/ml/hr 5.5 1.0 3.4 0.3 3.1 0.5 3.4 0.4
PRA 12.0 2.5 8.8 1.4 7.3 1.7 9.0 1.6
All, pg/in! 28.0 3.0 22 2.0 25 3.0 21 2.0All —11.9 4.7
—5.8 1.6
—8.8 2.2
—5.3 1.8
UNaV, p.Eq/min 7.2 2.2 15.8 3.3 19.8 16.8 15.2 3.0UNV 6.8 3.1 5.3 1.9 4.7 3.8 5.4 2.1
UKV, i.Eq/min 64.4 7.6 71.2 4.4 62.3 14.5 72.4 4.5
LUKV —20.9 6.4 —11.8 4.6 —5.0 12.5 —12.7 5.0
aCer is creatinine clearance; UNaV, sodium excretion; UKV, potassium excretion, Other abbreviations are defined in Table I. Values are the
means SEM.
It is reasonable to ascribe at least part of the modest increase
in RBF induced in the subjects on a high salt intake to some
factor other than angiotensin, such as kinin accumulation
secondary to kininase II inhibition. SQ 20881 increased RBF in
dogs, with a concomitant increase in renal venous or urinary
kinin concentration [13—15]. Certainly such agents do potentiate
bradykinin via kininase II inhibition [161. No studies have been
reported, however, as to how well-sustained the changes in
renal venous or urinary kinins are.
Accumulation of a vasodilator prostaglandin, because of
some direct action of this agent on this system, is another
alternative [17]. Converting enzyme inhibition, however, did
not increase renal prostaglandin release in either the rabbit [18]
or the dog [151. The substantially larger response in subjects on
a restricted sodium intake seems straightforward: All is a
potent renal vasoconstrictor, the concentration of this constric-
tor agent rises with restriction of sodium intake, and the rise is
reversed by converting enzyme inhibition.
A potentiated renal vascular response to captopril occurred
in patients with essential hypertension whether they were
ingesting a restricted or liberal sodium intake. Such a response
has been documented in essential hypertension following non-
specific vasodilator agents such as acetylcholine and dopamine
[1], more specific agents such as phentolamine [1] and teprotide
[4]. This is the first documentation of a potentiated renal
vascular response to an agent taken by mouth in patients with
essential hypertension, an observation that provides further
evidence for a functional abnormality involving the renal vascu-
lature in this puzzling disease: organic lesions, it is reasonable
to surmise, would be fixed and unresponsive to a vasodilator
agent.
The mechanism of the enhanced renal vascular response in
the patient with essential hypertension is of some interest. The
fall in plasma All concentration was identical in the patients
with essential hypertension and the normal subjects on each
diet. If, however, a well-documented sensitization of vascular
responsiveness in essential hypertension involving the renal
blood supply does occur, a normal All concentration could
have induced a potentiated response. On that basis an identical
fall in the concentration of this vasoconstrictor would induce a
larger increase in RBF. As in earlier studies [4], plasma
bradykinin concentrations showed a transient rise in the pa-
tients with essential hypertension, but no measurements were
made of renal venous or urinary concentrations.
Some insight into the responsible mediator might be provided
by the angiographic response. Both bradykinin and prostaglan-
dins induce widespread dilatation of the renal vascular tree,
involving the interlobar and arcuate arteries, as well as the
arterioles [19]. Angiotensin, on the other hand, has little if any
effect on proximal levels of the arterial blood supply of the
kidney, with its action primarily in the cortical vessels too small
to be visualized on arteriography [20]. Captopril had little if any
effect on more proximal levels of the renal arterial tree in
normal subjects and in patients with essential hypertension,
favoring angiotensin as the mediator.
In normal subjects, GFR showed a small but consistent
reduction in response to captopril, consistent with many earlier
studies in animals [14]. Whether this was due to the fall in
arterial pressure or dominant efferent arteriolar dilatation is not
known. What is clear is that patients with essential hyperten-
sion differed in this regard, too, despite a larger fall in arterial
pressure. For essential hypertensives taken as a group, GFR
did not fall, a response that was significantly different from
normal. As in the earlier studies with teprotide, however, there
was utility in subclassifying the patients: GFR showed a consis-
tent and substantial rise in patients in whom the control
creatinine clearance was below our lower limit of normal [3]. In
the earlier study, the response was documented during the first
several hours of teprotide administration [3]. In this study the
followup evaluation was made after 1 or 2 days of treatment; an
increase was still demonstrable in this subgroup. Given the
potential importance of the renal response in the pathogenesis
of hypertension, a high priority must be placed on establishing
how well this salutary response is sustained in the ensuing
months and years. The increase in GFR may well contribute to
an enhanced ability of the kidney to handle sodium.
Acute pharmacologic interruption of the renin-angiotensin
system can lead to a natriuresis through local, intrarenal
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mechanisms, as identified by their local effectiveness when
given into the renal artery [22] and by the rapidity of the
response, which occurs too quickly for the fall in aldosterone to
play a role [31. A sustained natriuresis and a negative sodium
balance, well-documented over days in animals [141 and in man
[6, 7], probably also reflects a reduced impact of aldosterone on
the kidney. The renal vascular response documented in this
study may well have contributed as well: although the natriure-
sis was not increased in the hypertensives, their larger fall in
arterial blood pressure may have been offset by the enhanced
renal vasodilatation.
Systems analysis has made it clear that the kidney must lie at
the center of sustained hypertension, whatever initiates the
elevation in arterial blood pressure [23]. An increase in renal
vascular resistance has been one of the most consistent abnor-
malities documented in essential hypertension, and must be
considered to be one of several candidates in the pathogenesis
[2]. It is reasonable to ask whether the increase in RBF that this
agent induces, without a reduction in GFR, and at least under
some circumstances with an absolute increase in GFR, can
account—at least in part—for the sustained effectiveness in
patients with the treatment-resistant hypertension. If a sus-
tained response can be documented in such patients, and does
not occur in patients in whom captopnl was ineffective, this will
provide one of the most compelling arguments for the role of the
kidney in the pathogenesis of at least sustained, treatment-
resistant hypertension.
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